TIAA CREF Investment Management LLC decreased its position in Cambrex Corporation (NYSE:CBM) by 39.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 113,673 shares of the biotechnology company’s stock after selling 72,740 shares during the quarter. TIAA CREF Investment Management LLC owned 0.35% of Cambrex Corporation worth $6,792,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its stake in shares of Cambrex Corporation by 9.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 150 shares during the period. Creative Planning raised its stake in shares of Cambrex Corporation by 162.6% in the 2nd quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,093 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Cambrex Corporation in the 1st quarter valued at about $109,000. Riverhead Capital Management LLC raised its stake in shares of Cambrex Corporation by 90.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,264 shares during the period. Finally, Dubuque Bank & Trust Co. raised its stake in shares of Cambrex Corporation by 3.3% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 2,697 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 87 shares during the period.

In related news, CEO Steven M. Klosk sold 4,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the sale, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven M. Klosk sold 12,000 shares of the company’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total transaction of $618,360.00. Following the completion of the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $4,912,251.84. The disclosure for this sale can be found here. Insiders have sold a total of 28,000 shares of company stock worth $1,574,880 in the last three months. Insiders own 2.48% of the company’s stock.

Several research firms have issued reports on CBM. BidaskClub downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. ValuEngine raised Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $65.67.

ILLEGAL ACTIVITY WARNING: This news story was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/10/13/tiaa-cref-investment-management-llc-sells-72740-shares-of-cambrex-corporation-cbm.html.

Shares of Cambrex Corporation (CBM) opened at 53.50 on Friday. The firm has a market cap of $1.75 billion, a P/E ratio of 19.49 and a beta of 2.28. The firm has a 50 day moving average price of $53.07 and a 200 day moving average price of $55.46. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95.

Cambrex Corporation (NYSE:CBM) last released its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.76. The company had revenue of $134.55 million for the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The business’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 EPS. Analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current year.

Cambrex Corporation Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.